Table 2.
Characteristics of the patients included in the analysis. PET (positron emission tomography) features from the baseline 60-minute scan. UV1 = UV1 telomerase vaccine. ECOG = Eastern Cooperative Oncology Group performance status. Best overall response according to mRECIST (modified Response Criteria in Solid Tumours) and iRECIST (immune RECIST). MTV = metabolic tumour volume. TLG = total lesion glycolysis. SUVmax = maximum standardised uptake value. SUVpeak = peak standardised uptake value. NLR = neutrophil-to-lymphocyte-ratio
| Patient characteristic | N= 1001 |
|---|---|
| Age | 71 (64, 75) |
| Gender | |
| Female | 23 (23%) |
| Male | 77 (77%) |
| Treatment alarm | |
| +UVI | 49 (49%) |
| -UVI | 51 (51%) |
| ECOG | |
| ECOG 0 | 30 (30%) |
| ECOG 1 | 70 (70%) |
| PD-L1 | |
| PD-L1 negative | 55 (55%) |
| PD-L1 positive | 14 (14%) |
| Unknown | 31 (31%) |
| Histology | |
| Epitheloid | 77 (80%) |
| Non-epitheloid | 19 (20%) |
| Unknown | 4 |
| Best overall response | |
| Progressive disease | 25 (25%) |
| Stable disease | 53 (53%) |
| Partial response | 18 (18%) |
| Unknown | 4 (4%) |
| MTV (cm3) | 196 (44, 377) |
| Unknown | 1 |
| TLG | 839 (227, 1916) |
| Unknown | 1 |
| SUVmax | 14 (10, 17) |
| SUVpeak | 9.6 (6.7, 13.1) |
| NLR | 3.3 (2.1, 5.2) |
| Unknown | 3 |
1Median (OQR; n (%)